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Abstract: Despite the large variety of modified nucleosides
that have been reported, the preparation of constrained 4’-
spirocyclic adenosine analogues has received very little at-
tention. We discovered that the [2+2]-cycloaddition of di-
chloroketene on readily available 4’-exo-methylene furanose
sugars efficiently results in the diastereoselective formation
of novel 4’-spirocyclobutanones. The reaction mechanism
was investigated via density functional theory (DFT) and
found to proceed either via a non-synchronous or stepwise
reaction sequence, controlled by the stereochemistry at the
3’-position of the sugar substrate. The obtained dichlorocy-
clobutanones were converted into nucleoside analogues,
providing access to a novel class of chiral 4’-spirocyclobutyl
adenosine mimetics in eight steps from commercially avail-
able sugars. Assessment of the biological activity of de-
signed 4’-spirocyclic adenosine analogues identified potent
inhibitors for protein methyltransferase target PRMT5.
In recent years, mimetics of S-adenosyl-l-methionine (SAM, 1)
have found applications in drug discovery as protein methyl-
transferase (PMT) inhibitors for oncology targets,[1] as exempli-
fied by PRMT5 inhibitor LLY-283 (2)[2] and the clinical candidate
pinometostat (3) for DOT1L[3] (Figure 1). These selected exam-
ples indicate that the nucleoside moiety of SAM (1) is generally
well conserved, whereas diverse modifications at the 5’-posi-
tion of the adenosine analogues are tolerated. Consequently,
this encourages an exploration of the chemical space for the
discovery of selective SAM (1) analogues for methyltransferase
targets of interest.
An interesting example of a constrained SAM (1) analogue
and potent (35 nm) methyltransferase inhibitor for PRMT5 is
the natural product dehydrosinefungin (4),[4] for which no total
synthesis has been described. The impact of the 4’-exocyclic
double bond in 4 as a conformational constraint is emphasized
by the observation that the saturated analogue of 4 (sinefun-
gin) is nearly 250-fold less potent on the same target, and dis-
plays a poor selectivity against a panel of methyltransferases.[5]
Figure 1. Examples of SAM analogues as methyltransferase inhibitors and
undescribed spirocyclic scaffold 5.
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In this respect, the incorporation of a spirocyclobutyl ring can
be considered as a mimetic of the exocyclic alkene in dehydro-
sinefungin (4), with the potential to identify novel, biologically
active structurally constrained SAM (1) analogues. Indeed, con-
formational restriction via cyclization is a frequently used ap-
proach in drug discovery[6] and has proven to be a valuable
strategy towards nucleoside analogues with an enhanced affin-
ity and specificity for the nucleoside binding site in proteins.[7]
Remarkably, despite the multiple examples of 5’ modified
nucleosides, the preparation of 4’-spirocyclobutyl adenosine
scaffolds of type 5 has not been reported. Focussing on 4’-spi-
rocarbocyclic nucleosides, only few examples describe 4’-spiro-
cyclopentyl[8] and -propyl[9] nucleoside analogues, which are
typically prepared via lengthy synthetic routes or display limit-
ed opportunity for diversification of the spirocyclic scaffold
structures. The development of a strategy that enables an effi-
cient synthesis towards unknown adenosine core scaffold 5 is
thus of high interest to obtain innovative platform building
blocks that can be used in medicinal chemistry for the design
of constrained analogues of SAM (1).
In previous reports, Redlich et al. described the synthesis of
4’-spirocyclic furanoses of type 7 using a [2+2]-cycloaddition
of dichloroketene on exo-ethylidene furanose substrates 6a
and 6b, affording dichlorocyclobutanones 7a and 7b, respec-
tively (Scheme 1).[10] Although this is an interesting transforma-
tion, such cycloaddition on the corresponding ribose deriva-
tive 8 would generate far more potential as novel building
block for nucleoside analogues, however, subjecting exo-ethyli-
dene riboside 8 to identical cycloaddition conditions resulted
exclusively in the formation of side product 9. The further deri-
vatization of cyclobutanones 7a and 7b was not investigated,
nor have any efforts been described to prepare the corre-
sponding nucleoside analogues. Despite the failure of the
[2+2]-cycloaddition with dichloroketene on ribose analogue 8,
we set out to evaluate the potential of 4’-exo-methylene ribo-
sides substrates (type 10, Scheme 1), as this could directly
result in unsubstituted dichlorocyclobutanones of type 11. An
attractive asset of this approach is that substrates of type 10
can be readily prepared from chiral pool sugars on multigram
scale.[11]
To obtain 4’-spirocyclic adenosine analogues of type 5, dif-
ferent types of protected 4’-exo-methylene substrates were
prepared. In contrast to the failed cycloaddition reaction on
ribose analogue 8, we unexpectedly observed that when sub-
strate 12a was initially subjected to standard [2+2]-cycloaddi-
tion conditions with dichloroketene,[10] a clean and diastereose-
lective transformation towards dichlorocyclobutanone 13a was
obtained (Scheme 2). Encouraged by this, 4’-exo-methylene
substrates 12b and 12c were evaluated using identical condi-
tions, which also resulted in a diastereoselective reaction to
afford cycloadducts 13b and 13c, respectively. In all cases, the
facial selectivity of the [2+2]-cycloaddition is directed by the 3’
substituent, resulting in optically pure dichlorocyclobutanone-
s 13a–13c. Accordingly, the synthesis of stable dichlorocyclo-
butanones 13a and 13c was successfully reproduced on multi-
gram scale.
Scheme 1. Previous work and current study.[12]
Scheme 2. [2+2]-Cycloadditions on 4’-exo-methylene furanoses 12a–12c
(ribose) and 14a–14b (xylose), affording cycloadducts 13a–13c and 15a–
15b, respectively; [a] after reaction work-up, [b] recrystallized.
Chem. Eur. J. 2019, 25, 15419 – 15423 www.chemeurj.org T 2019 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim15420
Full Paper
To substantiate the observed stereoselectivity in the [2+2]-
cycloaddition on substrates 12a–12c, the energy profiles of
the approach from both the a and b faces were calculated
using DFT. These results were found to corroborate the experi-
mental observations, that is, the observed approach of dichlor-
oketene from the b face towards 13a–13c was found to pro-
ceed via a non-synchronous concerted reaction mechanism,
which corresponds to a lower energy transition state com-
pared to an approach from the a face. Indeed, calculations for
the addition of the ketene at the a face showed that a second
energy barrier (16c, Figure 2) needs to be overcome through a
two-step mechanism, as displayed for cycloadduct 13c.
Interestingly, when comparing our findings to the reported
synthesis of 7a and 7b starting from 4’-exo-ethylidene 6a and
6d, the opposite facial selectivity is observed. Moreover, DFT
calculations of the reaction mechanism towards cycload-
duct 7b are supportive for the observed addition at the a face
of 6b. To substantiate these observations, we verified if the
stereoselectivity of the cycloaddition can be controlled via
steric interactions at the 3’-position of the furanose ring using
4’-exo-methylene substrates 14a–14b. This hypothesis could
be verified as the structures of cycloadducts 15a–15b, ob-
tained as single isomers, were elucidated via single-crystal X-
ray diffraction (sc-XRD)[13] and found to be opposite compared
to 13a–13c (Scheme 2). The stereochemistry at the 3’-position of
the furanose ring is thus directing the approach of dichloroke-
tene to either the a or the b face, enabling stereoselective access
to both facial isomers by selecting the appropriate substrate.
Having multigram quantities of 4’-spirocyclic furanoses 13a
and 13c in hand, a reductive dechlorination using zinc and
acetic acid afforded ketones 17a and 17b, respectively
(Scheme 3). At this stage, the stable reaction products 17a and
17b could be efficiently purified via silica gel chromatography
and were isolated in good yields. Consecutively, the reduction
of ketone 17a showed a high selectively (94%) for cis-iso-
mer 18a when LiAlH4 was used as reducing agent. A more ex-
tensive screening of reduction conditions was performed on
ketone 17b, where the highest selectivity towards cis-iso-
mer 19a was noticed with NaBH4 in methanol at low tempera-
tures. The preference for cis-isomers 18a and 19a is believed
to be a result of unfavourable electrostatic repulsions between
the endo-cyclic oxygen of the furanose ring and the hydride,
which is in accordance with literature reports on 3-alkoxycyclo-
butanone reductions towards cis-3-alkoxycyclobutanols.[14] To
increase the potential of 4’-spirocyclobutyl furanoses as plat-
form building blocks towards a range of novel constrained nu-
cleoside analogues, access to the corresponding trans iso-
mers 18b and 19b was desired. A Mitsunobu inversion was
successfully applied on alcohols 18a and 19a, affording the
corresponding benzoates 20a and 21a, allowing at the same
time an efficient separation of the minor isomer by silica gel
chromatography.
With the purpose of transforming spirocyclic scaffolds 21a
and 21b into corresponding adenosine analogues, Vorbreggen
glycosylation was planned to introduce the nucleobase. To this
end, furanoses 21a and 21b were reacted with the in situ sily-
lated 6-chloropurine (22), followed by the addition of trime-
thylsilyl triflate (TMSOTf) and heating to 80 8C (Scheme 4).
Using these conditions, we were pleased to observe a stereo-
selective and high yielding conversion from 21a and 21b to-
wards the desired b-N9 nucleosides 23a and 23b, respectively.
Final deprotection and amine substitution of the 6-chloropur-
ine moiety in 23a and 23b with ammonia proceeded efficient-
ly in one step, affording the desired spirocyclic adenosine ana-
logues 5a and 5b in high yields.
Next, we investigated the ring puckering of 5a and 5b be-
cause the substitution of the furanose ring is known to have
Figure 2. Gibbs free energy diagram of dichloroketene approaching from
the b (red) and a (black) face to afford 13c.
Scheme 3. Reduction of dichlorocyclobutanones 13a and 13c to alcohol-
s 18a and 19a, respectively, and Mitsunobu inversion. Reduction conditions:
LiAlH4, THF, @78 8C (18), NaBH4, MeOH, @78 8C (19).
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an important impact on the adopted conformation and hence,
affects the biological properties in nucleosides and corre-
sponding oligonucleotides.[15] At first, sc-XRD clearly demon-
strated that 4’-spironucleoside 5a adopts a South (2’-endo)
conformation in the crystal lattice. Additionally, NMR spectros-
copy was used to relate the 1H–1H scalar couplings (3J1’–2’) to
the relative percentage of North/South ring puckers,[16] which
showed a preference for the South conformation for both cis
(5b) and trans (5a) nucleoside analogues of 73 and 69%, re-
spectively.[17] Furthermore, vibrational circular dichroism (VCD)
was employed to study the conformation of 5a and 5b, as
this technique offers the advantage that the experimental
spectral data can be validated via comparison with in silico
lowest energy conformations.[18] Also in this case, a preference
for a South ring puckering was established for spirocyclic nu-
cleosides analogues 5a and 5b. These results are supportive
for expanding novel constrained scaffolds 5a and 5b to create
ligands for protein methyltransferase PRMT5, since several co-
crystal structures with SAM (1) analogues sinefungin and dehy-
drosinefungin (4) demonstrate that South ring puckering is a
common feature, whereas the ring conformation of sinefungin
bound to other methyltransferases does not always adopt a
South ring pucker.[19]
To demonstrate that novel 4’-spirocyclic adenosine scaffolds
(5a–5b) can be used to design SAM (1) competitive inhibitors
of PMTs, we introduced a 2-aminoquinoline heterocycle at the
cyclobutanol moiety, as this has been reported to be a suitable
pharmacophore group in the preparation of PRMT5 inhibi-
tors.[20,21] To achieve this, we performed a Mitsunobu reaction
on cyclobutanols 18a and 18b using hydroxyquinoline 24. As
exemplified in Scheme 5 for building block 18b, this reaction
efficiently afforded the coupled product 25a with inversion of
stereochemistry at the cyclobutyl ring. Subsequently, a protect-
ing group switch was performed to convert 25a towards the
corresponding triacetate 26a in order to obtain a suitable sub-
strate for Vorbreggen glycosylation. Similar to the introduction
of 6-chloropurine (22) on substrates 21a and 21b (Scheme 4),
building block 26a was efficiently converted towards the de-
sired b-nucleoside intermediate, and sequential treatment with
aqueous ammonia in dioxane at elevated temperature afford
the envisioned compound 27a (Scheme 5).
Next, we examined the in vitro activity of novel 4’-spirocyclic
nucleoside analogues towards the PRMT5/MEP50 multimer
complex. In this assay, we first evaluated the unmodified 5a
(trans) and 5b (cis), which showed enzymatic activities in the
micromolar range (Table 1), corresponding to inhibition values
that are close to adenosine as a benchmark ligand.[20] This indi-
cates that the 4’-spirocyclobutyl ring is a tolerated modification
in the SAM binding pocket of PRMT5. Interestingly, the intro-
duction of a 2-aminoquinoline pharmacophore at the cyclobu-
tanol group in compounds 27a and 27b significantly im-
proved the activity compared to spirocyclic adenosine ana-
logues 5a and 5b, resulting in a nearly 400-fold increase in po-
tency for compound 27b (Table 1). These results clearly dem-
onstrate that novel core scaffolds of type 5 are valuable
building blocks for the preparation of target compounds for
SAM (1) competitive inhibition of PRMT5.
In conclusion, we have developed a scalable and diastereo-
selective [2+2]-cycloaddition reaction using dichloroketene on
4’-exo-methylene furanose substrates, resulting in the forma-
tion of optically pure 4’-spirocyclic dichlorocyclobutanones.
Calculations by DFT showed that the reaction proceeds via a
Scheme 4. Vorbreggen glycosylation and deprotection towards 4’-spirocyclic
adenosine analogues 5a and 5b.
Scheme 5. Mitsunobu reaction on spirocyclobutanol 18b and Vorbreggen
glycosylation towards compounds 27a and 27b (in analogy, not depicted).
Table 1. Inhibition potency of 5a–5b and 27a--27b for PRMT5:MEP50
complex measured at 10 nm PRMT5 concentration.
R Cmpd IC50 Cmpd IC50
H 5a 3.52 mM 5b 5.69 m
27b 9.42 nm 27a 31.1 nm
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nonsynchronous concerted or a stepwise mechanism, which is
controlled by the stereochemistry at the 3’-position of the
sugar substrate. Dichlorocyclobutanone scaffolds have been
converted towards the corresponding 4’-spirocyclobutanols
and these intermediates were found to be excellent substrates
for a stereoselective Vorbreggen glycosylation. This reproduci-
ble, high-yielding synthesis route enables access to multigram
quantities of a novel class of 4’-spirocyclobutyl adenosine ana-
logues in eight steps from commercially available sugar build-
ing blocks. A proof of concept was delivered that 4’-spirocyclic
building blocks can be transformed into potent inhibitors for
methyltransferase PRMT5.
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